Anemia impact and management: Focus on patient needs and the use of erythropoietic agents

Seminars in Oncology

Volumn 31, Issue SUPPL. 8, 2004, Pages 4-11

  Bokemeyer, Carsten ^a   Foubert, Jan ^b  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; EDUCATION; ELECTROLYTE DISTURBANCE; ERYTHROCYTE TRANSFUSION; FATIGUE; HEAD AND NECK CANCER; HODGKIN DISEASE; HUMAN; HYPOTHYROIDISM; LUNG CANCER; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; NUTRITION; NUTRITIONAL DEFICIENCY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; SIDE EFFECT; SLEEP;

ANEMIA; ERYTHROPOIETIN; FATIGUE; HUMANS; NEOPLASMS; QUALITY OF LIFE;

EID: 3042788947     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2004.04.003     Document Type: Conference Paper

References (36)

1. Gillespie T.W. Effects of cancer-related anemia on clinical and quality-of-life outcomes. Clin J Oncol Nurs. 6:2002;206-211
2. Gillespie T.W. Anemia in cancer. Cancer Nurs. 26:2003;119-128
3. Nowrousian M.R. Recombinant human erythropoietin in the treatment of cancer-related or chemotherapy-induced anaemia in patients with solid tumours. Med Oncol. 15:(suppl 1):1998;S19-S28
4. Skillings J.R., Rogers-Melamed I., Nabholtz J.-M. An epidemiological review of anaemia in cancer chemotherapy in Canada. Eur J Cancer. 31A:(suppl 5):1995;S5
5. Groopman J.E., Itri L.M. Chemotherapy-induced anemia in adults Incidence and treatment. J Natl Cancer Inst. 91:1999;1616-1634
6. ISIS Research Ltd. The treatment of cancer in Europe. 2000;ISIS, London, UK
7. Ludwig H., Fritz E. Anemia in cancer patients. Semin Oncol. 3:(suppl 7):1998;2-6
8. Vogelzang N.J., Breitbart W., Cella D. Patient, caregiver, and oncologists perceptions of cancer-related fatigue Results of a tripart assessment survey. Semin Hematol. 34:(suppl 2):1997;4-12
9. Cella D. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale A new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol. 34:(suppl 2):1997;13-19
10. Mock V., Dow K.H., Meares C.J., et al. Effects of exercise on fatigue, physical functioning, and emotional distress during radiation therapy for breast cancer. Oncol Nurs Forum. 24:1997;991-1000
11. Berger A.M., Farr L. The influence of daytime inactivity and nighttime restlessness on cancer-related fatigue. Oncol Nurs Forum. 26:1999;1663-1671
12. Blesch K., Paice J., Wickham R., et al. Correlates of fatigue in people with breast or lung cancer. Oncol Nurs Forum. 18:1991;81-87
13. Curt G.A., Breitbart W., Cella D., et al. Impact of cancer-related fatigue on the lives of patients New findings from the Fatigue Coalition. Oncologist. 5:2000;353-360
14. Crawford J., Cella D., Cleeland C.S., et al. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer. 95:2002;888-895
15. Payne J.K. The trajectory of fatigue in adult patients with breast and ovarian cancer receiving chemotherapy. Oncol Nurs Forum. 29:2002;1334-1340
16. Portenoy R.K., Itri L.M. Cancer-related fatigue Guidelines for evaluation and management. Oncologist. 4:1999;1-10
17. Barrett-Lee P.J., Bailey N.P., O'Brien M.E., et al. Large-scale UK audit of blood transfusion requirements and anaemia in patients receiving cytotoxic chemotherapy. Br J Cancer. 82:2000;93-97
18. Littlewood T.J., Bajetta E., Nortier J.W., et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy Results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 19:2001;2865-2874
19. Österborg A., Brandberg Y., Molostova V., et al. Epoetin Beta Hematology Study Group. Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin Beta, in hematologic malignancies. J Clin Oncol. 20:2002;2486-2494
20. Vansteenkiste J., Pirker R., Massuti B., et al. Aranesp 980297 Study Group. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst. 94:2002;1211-1220
21. Hedenus M., Adriansson M., San Miguel J., et al. Darbepoetin Alfa 20000161 Study Group. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies A randomized, double-blind, placebo-controlled study. Br J Haematol. 122:2003;394-403
22. Smith R.E., Tchekmedyian N.S., Chan D., et al. A dose- and schedule-finding study of darbepoetin alpha for the treatment of chronic anaemia of cancer. Br J Cancer. 88:2003;1851-1858
23. Glaspy J., Henry D., Patel R. Effects of darbepoetin alfa (Aranesp) timing with chemotherapy administration A randomized study. 2003;. Presented at the 8th International Conference on Geriatric Oncology: Cancer in the Elderly; November 21-22, (abstr 29 and poster)
24. Coiffier B. Advocating recombinant human erythropoietin as standard practice in Europe for treatment of cancer-related anaemia. Ann Oncol. 14:2003;804
25. Rizzo J.D., Lichtin A.E., Woolf S.H., et al. Use of epoetin in patients with cancer Evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol. 20:2002;4083-4107
26. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Cancer and treatment-related anaemia. Version 2. Available at: www.nccn.org/physician_gls/f_guidelines.html
27. Brown K.A., Esper P., Kelleher L.O., et al. Chemotherapy and biotherapy Guidelines and recommendations for practice. 2001;Oncology Nursing Society, Pittsburg, PA
28. Coackley A., Hutchinson T., Saltmarsh P., et al. Assessment and management of fatigue in patients with advanced cancer Developing guidelines. Int J Palliat Nurs. 8:2002;381-388
29. Caro J.J., Salas M., Ward A., et al. Anemia as an independent prognostic factor for survival in patients with cancer A systematic, quantitative review. Cancer. 91:2001;2214-2221
30. Van Belle S.J.F., Cocquyt V. Impact of haemoglobin levels on the outcome of cancers treated with chemotherapy. Crit Rev Oncol Haematol. 47:2003;1-11
31. Frommhold H., Guttenberger R., Henke M. The impact of blood hemoglobin content on the outcome of radiotherapy. Strahlenther Onkol. 17:(suppl 4):1998;31-34
32. Ludwig H., Fritz E., Leitgeb C., et al. Erythropoietin treatment for chronic anemia of selected hematological malignancies and solid tumors. Ann Oncol. 4:1993;161-167
33. Glaser C.M., Millesi W., Kornek G.V., et al. Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int J Radiat Oncol Biol Phys. 50:2001;705-715
34. Bohlius J.F., Langenspiepen S., Schwarzer G., et al. Does erythropoietin improve overall survival in the treatment of patients with malignant diseases? Results of a comprehensive meta-analysis. Blood. 102:2003;203a. (abstr 709)
35. Leyland-Jones B. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncology. 4:2003;459-460
36. Henke M., Laszig R., Rube C., et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy Randomised, double-blind, placebo-controlled trial. Lancet. 362:2003;1255-1260